Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/13/25 | UPLOAD | SEC-generated letter |
|
1 | |
| 08/12/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
6 | |
| 08/11/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 08/07/25 | S-3 | Registration statement under Securities Act of 1933 |
|
  |
212 |
| 08/07/25 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
|
159 |
| 08/07/25 | 8-K | Current report |
|
|
8 |
| 08/06/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 08/06/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 07/29/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 07/16/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
6 |
